A 29-year-old Hmong woman presented with 3 months of worsening imbalance and intermittent vertigo followed by right facial numbness, slurred/ nonsensical speech, and memory impairment. She reported generalized weakness, fatigue, and anorexia with more than 10 kg weight loss. She denied paresthesia, vision loss, nausea, vomiting, or hiccups. Neurologic examination revealed impaired short-term memory, expressive aphasia, mild right appendicular ataxia, and profound abulia.
AQP4, or other astroglial markers could not be performed.
The patient deteriorated during the hospitalization, with worsening abulia, aphasia, and akinesia. She was treated with 1 g of methylprednisolone daily for 5 days followed by a prednisone taper without benefit. The patient underwent plasmapheresis for 5 exchanges (1 blood volume per exchange with albumin replacement) and began to clinically improve. Repeat imaging showed reduction in contrast enhancement of the brain lesions (figure, A). She was treated with rituximab for ongoing immune suppression (1,000 mg IV 3 2 infusions with plans for repeat infusions after 6 months).
This case is notable for the simultaneous occurrence of CSF anti-NMDA receptor and serum anti-NMO/ AQP4 antibodies. Anti-NMDA receptor antibodies present in the CSF that are not found in the serum in patients with encephalitis are thought to correlate with clinical outcomes.
1 Anti-NMO/AQP4 antibodies typically are associated with transverse myelitis and optic neuritis and sometimes are associated with brainstem or cerebral involvement. 2 The sequential occurrence of NMO/NMO spectrum disorder followed by NMDA receptor encephalitis was recently reported in 5 patients. 3 The simultaneous occurrence of these CNS pathogenic antibodies with pathologic findings has not been previously reported. Although we do not know to what extent the anti-NMO/AQP4 and the anti-NMDA receptor autoantibodies contributed to the presentation, the clinical and radiographic features in this case suggest features of both NMO spectrum disorder and NMDA receptor encephalitis. Clinical and radiographic features that could be consistent with NMO include the brainstem syndrome with anorexia and radiographic involvement of the brainstem, hypothalamus, and optic chiasm. Similarly, cognitive impairment and akinesia along with the radiographic features of encephalitis might be due to NMDA receptor antibodies.
Other autoimmune diseases, including systemic lupus erythematosus, Sjögren syndrome, and myasthenia gravis, occur in patients with NMO. Many patients with NMO test seropositive for other autoantibodies. 4 More recently, anti-myelin oligodendrocyte glycoprotein antibodies were associated with a clinical presentation consistent with NMO. 5 We speculate that a mechanism underlying a breach in immune tolerance could be shared by CNS autoantibody-mediated diseases, resulting in the sequential occurrence of NMO and NMDA receptor encephalitis and possibly explaining the co-occurrence of these autoantibodies in our patient. An immunodominant AQP4 peptide recognized by T cells in patients with NMO has a high degree of homology to an ABC transporter from Clostridium species, suggesting that molecular mimicry might be involved in NMO pathogenesis. 6 Colonization of Clostridium or other bacterial species in the gut could promote immune responses that cross-react with the AQP4 and NMDA receptor proteins. Alternately, we speculate that NMO-related inflammation could "reveal" CNS antigens to the immune system, resulting in a secondary inflammatory response similar to that proposed for HSV and NMDA receptor encephalitis. 7 We suggest that patients presenting with encephalitis be systematically screened for the presence of anti-NMO/AQP4 and anti-NMDA receptor antibodies in serum and CSF.
